The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Somatic mutational profile of Merkel cell carcinoma treated with immune checkpoint blockade: Preliminary results from a planned multiplatform analysis.
 
Evan Rosenbaum
No Relationships to Disclose
 
Ciara Marie Kelly
Research Funding - AGIOS (Inst); Amgen (Inst); INCYTE (Inst); Merck (Inst)
 
Christopher Andrew Barker
Honoraria - Driver Group; Elsevier
Consulting or Advisory Role - Patient Resource; Pfizer
Speakers' Bureau - Omniprex
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Elekta (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Driver Group; Pfizer
 
Travis Adamson
Employment - Maxim Healthcare
 
Hannah Kiesler
Stock and Other Ownership Interests - Alexion Pharmaceuticals; Edwards Lifesciences; Gilead Sciences; Johnson & Johnson; Merck; Pfizer
 
Jasreet Hundal
No Relationships to Disclose
 
Alexander J. Paul
No Relationships to Disclose
 
Michael D. McLellan
No Relationships to Disclose
 
Jason Walker
No Relationships to Disclose
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Agios; Blueprint Medicines; Daiichi Sankyo; Eisai; EMD Serono; GlaxoSmithKline; Immune Design; Janssen; Lilly; Loxo; Nanocell Therapy; Novartis; Plexxikon
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Methods of Treating Metastatic Sarcoma Using Talimogene Laherparepvec (T-Vec) and Pembrolizumab Combination Therapy- 62/671,625
 
Daniel G. Coit
No Relationships to Disclose
 
Sandra P. D'Angelo
Consulting or Advisory Role - Amgen; EMD Serono; GlaxoSmithKline; Immune design; Incyte; Merck; Nektar
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); EMD Serono (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst)
Patents, Royalties, Other Intellectual Property - Phase II study of TVEC + pembrolizumab in sarcoma
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar